Literature DB >> 6188820

Chronic hypernatremia from a congenital defect in osmoregulation of thirst and vasopressin.

E Schaff-Blass, G L Robertson, R L Rosenfield.   

Abstract

An infant with microcephaly and delayed development was found to have chronic asymptomatic hypernatremia. Computerized brain tomography disclosed dysplasia of the midline structures, septum pellucidum and corpus collosum. Evaluation revealed defective osmoregulation, hypothalamic hypothyroidism, and hypogonadotropinism. He showed no desire to drink at plasma osmolalities over 330 mOsm/kg. His plasma vasopressin levels (less than or equal to 1.4 pg/ml) were inappropriately low relative to his high levels of plasma osmolality (greater than or equal to 310 mOsm/kg), which might be accounted for by either deficient neurohypophyseal vasopressin stores or disturbance of the hypothalamic osmoreceptors governing vasopressin. The first possibility was ruled out by demonstrating normal vasopressin response (167 pg/ml) to nonosmotic (emetic) stimulation. Under baseline conditions, his urine was concentrated up to 747 mOsm/kg and urine volume was low. With water loading, maximal water diuresis developed (urine osmolality 68 mOsm/kg), but his plasma osmolality remained in the hyperosmolar range (312 mOsm/kg). Treatment with a vasopressin analogue, desamino-D-arginine vasopressin, and forced hydration restored plasma osmolality and plasma sodium to normal. These findings indicate a severe defect in the hypothalamic osmoreceptors controlling thirst and vasopressin secretion with normal vasopressin stores and preserved vasopressin responsiveness to nonosmotic stimuli. To our knowledge, this report provides the first documentation of selective osmoreceptor defect in conjunction with congenital dysplasia of midline brain structures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188820     DOI: 10.1016/s0022-3476(83)80237-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Distinguishing between salt poisoning and hypernatraemic dehydration in children.

Authors:  Malcolm G Coulthard; George B Haycock
Journal:  BMJ       Date:  2003-01-18

2.  Hypothalamic failure as a sequela of heterozygous protein C deficiency?

Authors:  S Schmitt; K Auberger; T Fendel; W Kiess
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

3.  Hypothalamic adipic hypernatraemia syndrome with normal osmoregulation of vasopressin.

Authors:  Marta López-Capapé; Luz Golmayo; Gustavo Lorenzo; Nieves Gallego; Raquel Barrio
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

4.  Inappropriate secretion of antidiuretic hormone, polydipsia and hypothalamic calcifications.

Authors:  P Gross; A Wichmann; D Walb; J Hensen; S Abdelhamid
Journal:  Klin Wochenschr       Date:  1989-07-17

5.  Hypertriglyceridemia in Infants and Children with Hypernatremia.

Authors:  Fathelrahman E Ahmed; Mohamed F Lutfi
Journal:  Int J Health Sci (Qassim)       Date:  2015-07

6.  Adipsic diabetes insipidus following pituitary surgery for a macroprolactinoma.

Authors:  M Sherlock; A Agha; R Crowley; D Smith; C J Thompson
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

7.  Congenital pituitary cyst resulting in adipsic central diabetes insipidus and secondary hypernatremia in a cat.

Authors:  Janny Evenhuis; Steven E Epstein; Ann Della-Maggiore; Krystle L Reagan
Journal:  JFMS Open Rep       Date:  2021-02-27

8.  Successful treatment of hypodipsic/adipsic hypernatremia in a cat with lobar holoprosencephaly using oral desmopressin.

Authors:  Yoriko Akashi; Young Tae Park; Garrett S Oetelaar; Masahiro Murakami
Journal:  JFMS Open Rep       Date:  2022-03-23

9.  Adipsic Diabetes Insipidus-The Challenging Combination of Polyuria and Adipsia: A Case Report and Review of Literature.

Authors:  Rinkoo Dalan; Hanxin Chin; Jeremy Hoe; Abel Chen; Huiling Tan; Bernhard Otto Boehm; Karen SuiGeok Chua
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-18       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.